INTEGRA LIFESCIENCES HOLDINGS CORP Business Acquisition, Pro Forma Revenue
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Business Acquisition, Pro Forma Revenue of $1.43 billion for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-21.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2020-02-21
- INTEGRA LIFESCIENCES HOLDINGS CORP business acquisition, pro forma revenue for the quarter ending 2017-12-31 was $368.60M, a 43.66% decline year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP business acquisition, pro forma revenue for the quarter ending 2017-09-30 was $352.35M, a 29.34% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP business acquisition, pro forma revenue for the quarter ending 2017-06-30 was $360.88M, a 32.80% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP business acquisition, pro forma revenue for the quarter ending 2017-03-31 was $346.65M, a 34.88% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP business acquisition, pro forma revenue for fiscal 2017 was $1.43B, a 1.27% decline from fiscal 2016.
- INTEGRA LIFESCIENCES HOLDINGS CORP business acquisition, pro forma revenue for fiscal 2016 was $1.45B, a 53.93% increase from fiscal 2015.
- INTEGRA LIFESCIENCES HOLDINGS CORP business acquisition, pro forma revenue for fiscal 2015 was $940.00M, a 1.95% increase from fiscal 2014.
- INTEGRA LIFESCIENCES HOLDINGS CORP business acquisition, pro forma revenue for fiscal 2014 was $922.00M, a 14.81% increase from fiscal 2013.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 6 month as first filed | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month | Business Acquisition, Pro Forma Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $368.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $720.95M derived: sum of 2 quarters · filed 2020-02-21 | $1.08B derived: sum of 3 quarters · filed 2020-02-21 | $1.43B 10-K · filed 2020-02-21 | ||||
| 2017-09-30 | $352.35M 10-Q · filed 2018-11-01 | $713.23M derived: sum of 2 quarters · filed 2018-11-01 | $1.06B 10-Q · filed 2018-11-01 | $832.71M 10-Q · filed 2017-10-26 | $1.71B derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-06-30 | $360.88M 10-Q · filed 2018-07-26 | $707.54M 10-Q · filed 2018-07-26 | $553.63M 10-Q · filed 2017-07-26 | $1.36B derived: sum of 3 quarters · filed 2019-02-26 | $1.63B derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | $346.65M 10-Q · filed 2018-04-26 | $271.46M 10-Q · filed 2017-04-26 | $1.00B derived: sum of 2 quarters · filed 2019-02-26 | $1.27B derived: sum of 3 quarters · filed 2019-02-26 | $1.55B derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | $654.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $926.66M derived: sum of 2 quarters · filed 2019-02-26 | $1.20B derived: sum of 3 quarters · filed 2019-02-26 | $1.45B 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | $272.43M 10-Q · filed 2017-10-26 | $544.16M derived: sum of 2 quarters · filed 2017-10-26 | $792.67M 10-Q · filed 2017-10-26 | $1.04B derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $271.74M 10-Q · filed 2017-07-26 | $528.75M 10-Q · filed 2017-07-26 | $772.20M derived: sum of 3 quarters · filed 2018-03-01 | $1.01B derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-03-31 | $257.01M 10-Q · filed 2017-04-26 | $500.46M derived: sum of 2 quarters · filed 2018-03-01 | $735.98M derived: sum of 3 quarters · filed 2018-03-01 | $971.34M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-12-31 | $243.45M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $478.97M derived: sum of 2 quarters · filed 2018-03-01 | $714.33M derived: sum of 3 quarters · filed 2018-03-01 | $940.00M 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | $235.52M 10-Q · filed 2016-10-28 | $229.40M 10-Q · filed 2015-11-04 | $470.88M derived: sum of 2 quarters · filed 2016-10-28 | $696.56M 10-Q · filed 2016-10-28 | $677.74M 10-Q · filed 2015-11-04 | $961.76M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-06-30 | $235.36M 10-Q · filed 2016-07-28 | $460.83M 10-Q · filed 2016-07-28 | $241.80M 10-Q · filed 2015-07-31 | $726.24M derived: sum of 3 quarters · filed 2017-02-23 | $950.08M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-31 | $225.47M 10-Q · filed 2016-04-27 | $225.51M 10-Q · filed 2015-05-01 | $490.88M derived: sum of 2 quarters · filed 2017-02-23 | $714.72M derived: sum of 3 quarters · filed 2017-02-23 | ||||
| 2014-12-31 | $265.41M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $489.25M derived: sum of 2 quarters · filed 2017-02-23 | $922.00M 10-K · filed 2017-02-23 | $964.74M 10-K · filed 2015-02-27 | ||||
| 2014-09-30 | $223.84M 10-Q · filed 2015-11-04 | $656.58M 10-Q · filed 2015-11-04 | ||||||
| 2014-06-30 | $467.31M 10-Q · filed 2015-07-31 | |||||||
| 2013-12-31 | $803.07M 10-K · filed 2016-02-26 | $942.46M 10-K · filed 2015-02-27 | ||||||
| 2011-12-31 | $203.56M derived: 8-K 12 month − 10-Q 9 month · filed 2014-06-20 | $409.61M derived: sum of 2 quarters · filed 2014-06-20 | $613.52M derived: sum of 3 quarters · filed 2014-06-20 | $811.93M 8-K · filed 2014-06-20 | ||||
| 2011-09-30 | $206.05M 10-Q · filed 2012-10-24 | $409.97M derived: sum of 2 quarters · filed 2012-10-24 | $608.38M 10-Q · filed 2012-10-24 | $819.35M derived: sum of 4 quarters · filed 2012-10-24 | ||||
| 2011-06-30 | $203.92M 10-Q · filed 2012-07-31 | $402.33M 10-Q · filed 2012-07-31 | $613.30M derived: sum of 3 quarters · filed 2012-07-31 | $817.09M derived: sum of 4 quarters · filed 2012-07-31 | ||||
| 2011-03-31 | $198.41M 10-Q · filed 2012-04-26 | $409.38M derived: sum of 2 quarters · filed 2012-04-26 | $613.17M derived: sum of 3 quarters · filed 2012-04-26 | |||||
| 2010-12-31 | $210.97M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $414.77M derived: sum of 2 quarters · filed 2012-02-27 | $800.48M 10-K · filed 2012-02-27 | |||||
| 2010-09-30 | $203.79M 10-Q · filed 2011-10-31 | $589.50M 10-Q · filed 2011-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |